title: Inhibitory effects of glycoprotein isolated from Laminaria japonica on lipopolysaccharide-induced pro-inflammatory mediators in BV2 microglial cells.
abstract: Chronic microglial activation endangers neuronal survival through release of various toxic pro-inflammatory molecules; therefore, negative regulators of microglial activation have been identified as potential therapeutic candidates for use in treatment of many neurological diseases. In this study, we conducted an investigation of the inhibitory effects of glycoprotein isolated from Laminaria japonica (LJGP) on production of lipopolysaccharide (LPS)-induced pro-inflammatory mediators in BV2 microglial cells. Data from the study indicated that treatment with LJGP resulted in significant inhibition of excessive production of nitric oxide and prostaglandin E(2) in LPS-stimulated BV2 cells. LJGP also attenuated expression of inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines, including interleukin-1β and tumor necrosis factor-α. In addition, LJGP exhibited anti-inflammatory properties by suppression of nuclear factor-kappaB activation and downregulation of extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and Akt pathways. These findings suggest LJGP may provide neuroprotection through suppression of the proinflammatory pathway in activated microglia.
authors.affiliation: Dept of Pharmacy, Pusan Natl Univ, Busan, Republic of Korea.
authors.forename: Hye-Young
authors.initials: HY
authors.lastname: Park
authors.forename: Min-Ho
authors.initials: MH
authors.lastname: Han
authors.forename: Gi-Young
authors.initials: GY
authors.lastname: Kim
authors.forename: Nam Deuk
authors.initials: ND
authors.lastname: Kim
authors.forename: Taek-Jeong
authors.initials: TJ
authors.lastname: Nam
authors.forename: Yung Hyun
authors.initials: YH
authors.lastname: Choi
mesh_terms: D000818:Animals; D002460:Cell Line; D051546:Cyclooxygenase 2 / Q000235:genetics; D015232:Dinoprostone / Q000096:biosynthesis; D015536:Down-Regulation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects; D006023:Glycoproteins / Q000302:isolation & purification / Q000494:pharmacology*; D018836:Inflammation Mediators; D053583:Interleukin-1beta / Q000235:genetics; D007795:Laminaria / Q000737:chemistry*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D051379:Mice; D017628:Microglia / Q000187:drug effects / Q000378:metabolism*; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D009569:Nitric Oxide / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D048051:p38 Mitogen-Activated Protein Kinases / Q000235:genetics
chemical_list: D006023:Glycoproteins; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D008070:Lipopolysaccharides; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; D048049:Extracellular Signal-Regulated MAP Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D015232:Dinoprostone